JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on February 4, 2004; DOI: 10.1124/jpet.103.063370


0022-3565/04/3093-1273-1281$20.00
JPET 309:1273-1281, 2004
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.103.063370v1
309/3/1273    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ohtsuki, S.
Right arrow Articles by Terasaki, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ohtsuki, S.
Right arrow Articles by Terasaki, T.

ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

Mouse Reduced in Osteosclerosis Transporter Functions as an Organic Anion Transporter 3 and Is Localized at Abluminal Membrane of Blood-Brain Barrier

Sumio Ohtsuki, Tazuru Kikkawa, Shinobu Mori, Satoko Hori, Hitomi Takanaga, Masaki Otagiri, and Tetsuya Terasaki

Department of Molecular Biopharmacy and Genetics, Graduate School of Pharmaceutical Sciences (S.O., T.K., S.M., S.H., H.T., T.T) and New Industry Creation Hatchery Center (S.O., S.H., H.T., T.T.), Tohoku University, Sendai, Japan; Solution-Oriented Research for Science and Technology of Japan Science and Technology Agency, Japan (S.O., S.H., H.T., T.T.); and Faculty of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan (M.O.)

The "reduced in osteosclerosis" transporter (Roct), which shows decreased expression in the osteosclerosis (oc) mutant mouse, has high homology with rat and human organic anion transporter 3 (OAT3). However, its transport properties and involvement in bone turnover are poorly understood. Here, we examined Roct-mediated transport using a Xenopus laevis oocyte expression system. Roct-expressing oocytes exhibited uptake of [3H]estrone sulfate, [3H]p-aminohippuric acid, [3H]benzylpenicillin, [3H]estradiol 17{beta}-glucronide, [3H]indoxyl sulfate, [14C]indomethacin, [3H]homovanillic acid, [3H]cimetidine, [14C]glutarate, [14C]salicylic acid, and [3H]methotrexate. Furthermore, the uptake of [3H]benzylpenicillin by Roct coexpressed with Na+-dicarboxylate cotransporter was trans-stimulated by glutarate preloading, and [3H]estrone sulfate uptake showed a similar tendency, suggesting that Roct is a dicarboxylate exchanger. [3H]Benzylpenicillin uptake by Roct was inhibited by OAT3 substrates and inhibitors, and by sulfate or glucuronide conjugates, and compounds involved in bone turnover. Roct mRNA is expressed abundantly in the kidney and was also detected in the brain, choroid plexus, and eye. Immunohistochemical analysis revealed that Roct is localized in brain capillary endothelial cells. These results indicate that the transport properties and tissue distribution of Roct are similar to those of OAT3, suggesting that Roct functions as mouse OAT3. Because Roct is expressed in the kidney and at the blood-brain barrier, it may play a role in the excretion of substrates such as conjugates and bone turnover factors.


Received November 21, 2003; accepted February 3, 2004.

Address correspondence to: Prof. Tetsuya Terasaki, Department of Molecular Biopharmacy and Genetics, Graduate School of Pharmaceutical Sciences, Tohoku University, Aoba, Aramaki, Aoba-ku, Sendai 980-8578, Japan. E-mail: terasaki{at}mail.pharm.tohoku.ac.jp




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
K.-i. Hosoya, A. Makihara, Y. Tsujikawa, D. Yoneyama, S. Mori, T. Terasaki, S.-i. Akanuma, M. Tomi, and M. Tachikawa
Roles of Inner Blood-Retinal Barrier Organic Anion Transporter 3 in the Vitreous/Retina-to-Blood Efflux Transport of p-Aminohippuric Acid, Benzylpenicillin, and 6-Mercaptopurine
J. Pharmacol. Exp. Ther., April 1, 2009; 329(1): 87 - 93.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
R. Kikuchi, H. Kusuhara, N. Hattori, K. Shiota, I. Kim, F. J. Gonzalez, and Y. Sugiyama
Regulation of the Expression of Human Organic Anion Transporter 3 by Hepatocyte Nuclear Factor 1{alpha}/beta and DNA Methylation
Mol. Pharmacol., September 1, 2006; 70(3): 887 - 896.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
A. Bahn, M. Ljubojevic, H. Lorenz, C. Schultz, E. Ghebremedhin, B. Ugele, I. Sabolic, G. Burckhardt, and Y. Hagos
Murine renal organic anion transporters mOAT1 and mOAT3 facilitate the transport of neuroactive tryptophan metabolites
Am J Physiol Cell Physiol, November 1, 2005; 289(5): C1075 - C1084.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.